与痴呆风险,认知衰退和脑缩相关的抗抑郁药的使用
Ilse Vom Hofe1, Bruno H Stricker1, Meike W Vernooij1,2
1Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands.
概括
在没有认知障碍的老年人中使用抗抑郁药并没有增加痴呆风险,认知衰退或大脑缩. 这些发现支持在这个人群中安全处方抗抑郁药.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 药理学 药理学是指药理学的学科.
背景情况:
- 抗抑郁药物被广泛处方,特别是针对老年人.
- 对于老年人使用抗抑郁药对潜在的长期认知影响存在担忧.
研究的目的:
- 调查抗抑郁药使用与痴呆风险之间的关联.
- 评估抗抑郁药对老年人认知衰退和脑缩的影响.
主要方法:
- 对5511名没有痴呆症的参与者进行前性队列研究 (鹿特丹研究).
- 来自药房记录的抗抑郁药使用数据 (1991-2008).
- 长期监测痴呆症发病率,认知功能和脑MRI (直到2018年).
主要成果:
- 总体而言,抗抑郁药的使用与痴呆症风险增加,认知能力下降或大脑缩无关.
- 三环抗抑郁药与从未使用的抗抑郁药相比,患痴呆症的风险略高,但没有剂量反应效应或与认知衰退/缩相关.
- 选择性血清素再吸收抑制剂 (SSRI) 与痴呆风险增加,认知能力下降或缩无关.
结论:
- 在认知健康的老年人中,抗抑郁药的使用并不总是与不良的长期认知结果有关.
- 这些发现表明,抗抑郁药物可以安全地给老年人开处方,而没有先前存在的认知障碍.
- 进一步的研究可能会探索特定的抗抑郁药类和长期影响.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
228
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
228
Dementia
113
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
113
Alzheimer's Disease: Treatment
184
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
184
Alzheimer's Disease: Overview
469
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
469
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
382
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
382
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
122
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
122


